부산대학교 도서관

A post hoc analysis of the SUSTAIN 6 trial evaluated the effect of once-weekly semaglutide on cardiovascular (CV) outcomes in people with type 2 diabetes (T2D) stratified by the number of vascular territories with atherosclerosis at baseline. The study found that semaglutide was associated with a consistent reduction in CV events across all groups, including those with polyvascular disease. The absolute risk reduction for CV events was greater in people with polyvascular disease, suggesting that they may derive greater benefit from semaglutide treatment due to their higher CV risk. However, the study had limitations, and further research is needed to confirm these findings. [Extracted from the article]